ADT for Prostate Cancer: Agonists vs Antagonists

Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapies (ADT) for treating prostate cancer, and claims that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.

• #education
• #lawrence_karsh
• #androgen_deprivation_therapy
• #adt
• #prostate_cancer
• #agonists
• #thomas_keane
• #antagonists